|Peer-Reviewed|December 23, 2020

January 2021
Volume 27
Issue 1

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Author(s)Brenna L. Brady, PhD, Matthew Lucci, MPH, Kathleen Wilson, MPH

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

eAPPENDIX Clinical and Economic Burden of Intravenous Paclitaxel

Articles in this issue

about 5 years ago

Article

ASH 2020: Clinical Updates

about 5 years ago

Article

ASH 2020: COVID-19 and Hematology

about 5 years ago

Article

ASH 2020: CAR T-Cell Therapy Updates

about 5 years ago

Article

ASH 2020: The Next Wave

about 5 years ago

Article

2020 SABCS: Topics in Precision Oncology

about 5 years ago

Article

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

about 5 years ago

peer-reviewed

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

about 5 years ago

peer-reviewed

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

about 5 years ago

peer-reviewed

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Patient Advocacy Helps Shape Clinical Trial Approvals, Policy Decisions: Debra Patt, MD, PhD, MBA, MPH

ByBrooke McCormick,Debra Patt, MD, PhD, MBA, MPH

January 16th 2026

Patient Perspectives Drive More Relevant, Feasible Clinical Research: Debra Patt, MD, PhD, MBA, MPH

ByBrooke McCormick,Debra Patt, MD, PhD, MBA, MPH

January 13th 2026

Improving Breast Cancer Outcomes in Young Patients Requires Whole-Person, Age-Specific Care: Yara Abdou, MD

ByBrooke McCormick,Yara Abdou, MD

January 10th 2026

Adam Brufsky, MD, PhD, University of Pittsburgh

Invest in Human Capital to Improve Breast Cancer Care Delays: Adam Brufsky, MD, PhD

ByMaggie L. Shaw,Adam Brufsky, MD, PhD

January 9th 2026

Genomic Tools Highlight Genetic Differences Linked to More Aggressive Breast Cancer in Latin Women: William Audeh, MD, MS

BySabrina McCrear,William Audeh, MD, MS

January 7th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Articles in this issue

Newsletter

Related Content

Patient Advocacy Helps Shape Clinical Trial Approvals, Policy Decisions: Debra Patt, MD, PhD, MBA, MPH

Patient Perspectives Drive More Relevant, Feasible Clinical Research: Debra Patt, MD, PhD, MBA, MPH

Improving Breast Cancer Outcomes in Young Patients Requires Whole-Person, Age-Specific Care: Yara Abdou, MD

Invest in Human Capital to Improve Breast Cancer Care Delays: Adam Brufsky, MD, PhD

Genomic Tools Highlight Genetic Differences Linked to More Aggressive Breast Cancer in Latin Women: William Audeh, MD, MS

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Novel CLL Therapies Prompt New Treatment Considerations

Congress Unveils Massive Funding Bill to Avert Shutdown

Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma

ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC

Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care